Michael A. Morse, MD, discusses a number of key trials that have broadened the treatment landscape of mCRC, the importance of toxicity management in this setting, and other ongoing developments in GI cancers.
Caroline Seymour
Advertisement
Articles by Caroline Seymour
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
June 2026 in Oncology: A Look Back at FDA Approvals and Decisions
2
Orca-T Gains FDA Approval in Matched Donor Transplants
3
New Considerations Arise in Sequencing After Second Relapse in Multiple Myeloma
4
Chemo-Free Zanubrutinib Combo Bests Bendamustine in Frontline MCL
5